Would the incorporation of CellPryme-M into the manufacturing of an already approved (or clinically advanced) cell therapy product send that product back to phase 1 clinical trials?
If so, CellPryme-M may only be attractive to pre-clinical or phase 1 assets.
Anyone able to answer this question? If not, I'll email the company.
- Forums
- ASX - By Stock
- PTX
- CellPryme-M question
CellPryme-M question
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.43M |
Open | High | Low | Value | Volume |
4.4¢ | 4.4¢ | 4.2¢ | $3.506K | 81.90K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 33058 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.4¢ | 10640 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 33058 | 0.042 |
7 | 899173 | 0.041 |
10 | 772543 | 0.040 |
4 | 720000 | 0.039 |
2 | 450000 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.044 | 10640 | 2 |
0.045 | 122000 | 3 |
0.047 | 308000 | 3 |
0.049 | 189091 | 2 |
0.050 | 398954 | 5 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |